Search Results - "A Fasching, Peter"

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 by Slamon, Dennis J, Neven, Patrick, Chia, Stephen, Fasching, Peter A, De Laurentiis, Michelino, Im, Seock-Ah, Petrakova, Katarina, Bianchi, Giulia Val, Esteva, Francisco J, Martín, Miguel, Nusch, Arnd, Sonke, Gabe S, De la Cruz-Merino, Luis, Beck, J Thaddeus, Pivot, Xavier, Vidam, Gena, Wang, Yingbo, Rodriguez Lorenc, Karen, Miller, Michelle, Taran, Tetiana, Jerusalem, Guy

“…Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative…”
Get full text

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes by VON MINCKWITZ, Gunter, UNTCH, Michael, JACKISCH, Christian, KAUFMANN, Manfred, KONECNY, Gottfried E, DENKERT, Carsten, NEKLJUDOVA, Valentina, MEHTA, Keyur, LOIBL, Sibylle, BLOHMER, Jens- Uwe, COSTA, Serban D, EIDTMANN, Holger, FASCHING, Peter A, GERBER, Bernd, EIERMANN, Wolfgang, HILFRICH, Jörn, HUOBER, Jens

“…The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain. Tumor…”
Get full text

DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer by Teschendorff, Andrew E, Gao, Yang, Jones, Allison, Ruebner, Matthias, Beckmann, Matthias W., Wachter, David L., Fasching, Peter A., Widschwendter, Martin

“…Identifying molecular alterations in normal tissue adjacent to cancer is important for understanding cancer aetiology and designing preventive measures. Here…”
Get full text

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study by Hurvitz, Sara A, Martin, Miguel, Jung, Kyung Hae, Huang, Chiun-Sheng, Harbeck, Nadia, Valero, Vicente, Stroyakovskiy, Daniil, Wildiers, Hans, Campone, Mario, Boileau, Jean-François, Fasching, Peter A, Afenjar, Karen, Spera, Gonzalo, Lopez-Valverde, Vanesa, Song, Chunyan, Trask, Peter, Boulet, Thomas, Sparano, Joseph A, Symmans, W Fraser, Thompson, Alastair M, Slamon, Dennis

“…The KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) with docetaxel, carboplatin, trastuzumab plus P (TCH+P) for the…”
Get full text

Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients by RACK, Brigitte, SCHINDLBECK, Christian, FEHM, Tanja, SCHNEEWEISS, Andreas, LICHTENEGGER, Werner, BECKMANN, Matthias W, FRIESE, Klaus, PANTEL, Klaus, JANNI, Wolfgang, JÜCKSTOCK, Julia, ANDERGASSEN, Ulrich, HEPP, Philip, ZWINGERS, Thomas, FRIEDL, Thomas W. P, LORENZ, Ralf, TESCH, Hans, FASCHING, Peter A

“…Circulating tumor cells (CTCs) have been shown to predict reduced survival outcomes in metastatic breast cancer. CTCs were analyzed in 2026 patients with early…”
Get full text

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial by Stevic, Ines, Müller, Volkmar, Weber, Karsten, Fasching, Peter A, Karn, Thomas, Marmé, Frederic, Schem, Christian, Stickeler, Elmar, Denkert, Carsten, van Mackelenbergh, Marion, Salat, Christoph, Schneeweiss, Andreas, Pantel, Klaus, Loibl, Sibylle, Untch, Michael, Schwarzenbach, Heidi

“…The focus of this study is to identify particular microRNA (miRNA) signatures in exosomes derived from plasma of 435 human epidermal growth factor receptor 2…”
Get full text

Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer by Janni, Wolfgang J, Rack, Brigitte, Terstappen, Leon W M M, Pierga, Jean-Yves, Taran, Florin-Andrei, Fehm, Tanja, Hall, Carolyn, de Groot, Marco R, Bidard, François-Clement, Friedl, Thomas W P, Fasching, Peter A, Brucker, Sara Y, Pantel, Klaus, Lucci, Anthony

“…Although unequivocal evidence has shown the prognostic relevance of circulating tumor cells (CTC) in the peripheral blood of patients with metastatic breast…”
Get full text

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer by Ingold Heppner, Barbara, Untch, Michael, Denkert, Carsten, Pfitzner, Berit M, Lederer, Bianca, Schmitt, Wolfgang, Eidtmann, Holger, Fasching, Peter A, Tesch, Hans, Solbach, Christine, Rezai, Mahdi, Zahm, Dirk M, Holms, Frank, Glados, Manfred, Krabisch, Petra, Heck, Esther, Ober, Angelika, Lorenz, Petra, Diebold, Kurt, Habeck, Jörg-Olaf, Loibl, Sibylle

“…We elucidated the value of tumor-infiltrating lymphocytes (TIL) as an independent predictor for pathologic complete response (pCR) rate and as a prognostic…”
Get full text

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial by von Minckwitz, Gunter, Prof, Schneeweiss, Andreas, Prof, Loibl, Sibylle, Prof, Salat, Christoph, MD, Denkert, Carsten, Prof, Rezai, Mahdi, Prof, Blohmer, Jens U, Prof, Jackisch, Christian, Prof, Paepke, Stefan, MD, Gerber, Bernd, Prof, Zahm, Dirk M, MD, Kümmel, Sherko, MD, Eidtmann, Holger, MD, Klare, Peter, MD, Huober, Jens, Prof, Costa, Serban, Prof, Tesch, Hans, Prof, Hanusch, Claus, MD, Hilfrich, Jörn, Prof, Khandan, Fariba, MD, Fasching, Peter A, Prof, Sinn, Bruno V, MD, Engels, Knut, MD, Mehta, Keyur, MBA, Nekljudova, Valentina, PhD, Untch, Michael, Prof

“…Summary Background Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist…”
Get full text

MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer by Kahraman, Mustafa, Röske, Anne, Laufer, Thomas, Fehlmann, Tobias, Backes, Christina, Kern, Fabian, Kohlhaas, Jochen, Schrörs, Hannah, Saiz, Anna, Zabler, Cassandra, Ludwig, Nicole, Fasching, Peter A., Strick, Reiner, Rübner, Matthias, Beckmann, Matthias W., Meese, Eckart, Keller, Andreas, Schrauder, Michael G.

“…Breast cancer is a heterogeneous disease with distinct molecular subtypes including the aggressive subtype triple-negative breast cancer (TNBC). We compared…”
Get full text

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups by UNTCH, Michael, FASCHING, Peter A, STICKELER, Elmar, HARBECK, Nadia, HÖSS, Cornelia, KAHLERT, Steffen, BECK, Thomas, FETT, Werner, MEHTA, Keyur M, VON MINCKWITZ, Gunter, LOIBL, Sibylle, KONECNY, Gottfried E, HASMÜLLER, Stephan, LEBEAU, Annette, KREIENBERG, Rolf, CAMARA, Oumar, MÜLLER, Volkmar, DU BOIS, Andreas, KÜHN, Thorsten

“…To evaluate efficacy and safety of epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab as neoadjuvant treatment in patients with human…”
Get full text

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment by Fasching, Peter A, Heusinger, Katharina, Haeberle, Lothar, Niklos, Melitta, Hein, Alexander, Bayer, Christian M, Rauh, Claudia, Schulz-Wendtland, Ruediger, Bani, Mayada R, Schrauder, Michael, Kahmann, Laura, Lux, Michael P, Strehl, Johanna D, Hartmann, Arndt, Dimmler, Arno, Beckmann, Matthias W, Wachter, David L

“…The pathological complete response (pCR) after neoadjuvant chemotherapy is a surrogate marker for a favorable prognosis in breast cancer patients. Factors…”
Get full text

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer by von Minckwitz, Gunter, Eidtmann, Holger, Rezai, Mahdi, Fasching, Peter A, Tesch, Hans, Eggemann, Holm, Schrader, Iris, Kittel, Kornelia, Hanusch, Claus, Kreienberg, Rolf, Solbach, Christine, Gerber, Bernd, Jackisch, Christian, Kunz, Georg, Blohmer, Jens-Uwe, Huober, Jens, Hauschild, Maik, Fehm, Tanja, Müller, Berit Maria, Denkert, Carsten, Loibl, Sibylle, Nekljudova, Valentina, Untch, Michael

“…Bevacizumab added to neoadjuvant combination chemotherapy increased the rate of pathological complete response among patients with HER-2-negative early-stage…”
Get full text

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial by Untch, Michael, Prof, Loibl, Sibylle, MD, Bischoff, Joachim, MD, Eidtmann, Holger, MD, Kaufmann, Manfred, Prof, Blohmer, Jens-Uwe, Prof, Hilfrich, Jörn, Prof, Strumberg, Dirk, Prof, Fasching, Peter A, Prof, Kreienberg, Rolf, Prof, Tesch, Hans, Prof, Hanusch, Claus, MD, Gerber, Bernd, Prof, Rezai, Mahdi, MD, Jackisch, Christian, Prof, Huober, Jens, Prof, Kühn, Thorsten, Prof, Nekljudova, Valentina, PhD, von Minckwitz, Gunter, Prof

“…Summary Background We compared the efficacy and safety of the addition of lapatinib versus trastuzumab to anthracycline-taxane-based neoadjuvant chemotherapy…”
Get full text

Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study by Untch, Michael, Rezai, Mahdi, Loibl, Sibylle, Fasching, Peter A, Huober, Jens, Tesch, Hans, Bauerfeind, Ingo, Hilfrich, Jörn, Eidtmann, Holger, Gerber, Bernd, Hanusch, Claus, Kühn, Thorsten, du Bois, Andreas, Blohmer, Jens-Uwe, Thomssen, Christoph, Dan Costa, Serban, Jackisch, Christian, Kaufmann, Manfred, Mehta, Keyur, von Minckwitz, Gunter

“…PURPOSE Trastuzumab, a humanized antibody against the human epidermal growth factor receptor type 2 (HER2), has shown high efficacy in breast cancer. We…”
Get full text

Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial by Müller, Volkmar, Gade, Stephan, Steinbach, Bettina, Loibl, Sibylle, von Minckwitz, Gunter, Untch, Michael, Schwedler, Kathrin, Lübbe, Kristina, Schem, Christian, Fasching, Peter A., Mau, Christine, Pantel, Klaus, Schwarzenbach, Heidi

“…Trastuzumab and lapatinib are established treatments for patients with HER2 (human epidermal growth factor receptor 2)-positive breast cancer with different…”
Get full text

Molecular profiling of single circulating tumor cells with diagnostic intention by Polzer, Bernhard, Medoro, Gianni, Pasch, Sophie, Fontana, Francesca, Zorzino, Laura, Pestka, Aurelia, Andergassen, Ulrich, Meier‐Stiegen, Franziska, Czyz, Zbigniew T, Alberter, Barbara, Treitschke, Steffi, Schamberger, Thomas, Sergio, Maximilian, Bregola, Giulia, Doffini, Anna, Gianni, Stefano, Calanca, Alex, Signorini, Giulio, Bolognesi, Chiara, Hartmann, Arndt, Fasching, Peter A, Sandri, Maria T, Rack, Brigitte, Fehm, Tanja, Giorgini, Giuseppe, Manaresi, Nicolò, Klein, Christoph A

“…Several hundred clinical trials currently explore the role of circulating tumor cell (CTC) analysis for therapy decisions, but assays are lacking for…”
Get full text

Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials by Werutsky, Gustavo, Untch, Michael, Hanusch, Claus, Fasching, Peter A., Blohmer, Jens-Uwe, Seiler, Sabine, Denkert, Carsten, Tesch, Hans, Jackisch, Christian, Gerber, Bernd, Schneeweiss, Andreas, Link, Theresa, Krug, David, Huober, Jens, Rhiem, Kerstin, Kühn, Thorsten, Vladimirova, Valentina, Nekljudova, Valentina, Loibl, Sibylle

“…This pooled analysis aimed to evaluate locoregional recurrence (LRR) rates of breast cancer (BC) after neoadjuvant chemotherapy (NACT) and to identify…”
Get full text

Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis by Cortes, Javier, Haiderali, Amin, Huang, Min, Pan, Wilbur, Schmid, Peter, Akers, Katherine G, Park, Julie E, Frederickson, Andrew M, Fasching, Peter A, O'Shaughnessy, Joyce

“…Background Patients with triple-negative breast cancer (TNBC) are generally younger and more likely to experience disease recurrence and have the shortest…”
Get full text

Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial by Loibl, Sibylle, Treue, Denise, Budczies, Jan, Weber, Karsten, Stenzinger, Albrecht, Schmitt, Wolfgang D, Weichert, Wilko, Jank, Paul, Furlanetto, Jenny, Klauschen, Frederick, Karn, Thomas, Pfarr, Nicole, von Minckwitz, Gunter, Möbs, Markus, Jackisch, Christian, Sers, Christine, Schneeweiss, Andreas, Fasching, Peter A, Schem, Christian, Hummel, Michael, van Mackelenbergh, Marion, Nekljudova, Valentina, Untch, Michael, Denkert, Carsten

“…Next-generation sequencing (NGS) can be used for comprehensive investigation of molecular events in breast cancer. We evaluated the relevance of genomic…”
Get full text